(Reuters) - H Lundbeck A/S has agreed to buy US-based Longboard Pharmaceuticals in a $2.6 billion deal to boost its pipeline of treatments for neuro-rare conditions, the companies said on Monday.
Source: Investing.com

(Reuters) - H Lundbeck A/S has agreed to buy US-based Longboard Pharmaceuticals in a $2.6 billion deal to boost its pipeline of treatments for neuro-rare conditions, the companies said on Monday.
Source: Investing.com
© Analytic DC. All Rights Reserved.